FT-001
IRDs (RPE65 mutation)
Phase 2Active
Key Facts
About Frontera Therapeutics
Frontera Therapeutics is an emerging, international gene therapy company with a dual focus on innovative rAAV technology and efficient manufacturing. The company has built two proprietary platforms: EXACTE™ for vector design and AAVANCE™ for scalable, low-cost GMP production. Several of its programs, including FT-001 and FT-002, have advanced into Phase II clinical trials with regulatory designations, positioning the company competitively in key therapeutic areas. With R&D in Boston, operations in Shanghai, and manufacturing in Suzhou, Frontera is structured for global development.
View full company profile